RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
Author(s) -
Ephraim Ansa-Addo,
HuaiCheng Huang,
Brian Riesenberg,
Supinya Iamsawat,
Davis Borucki,
Michelle H. Nelson,
Jin Hyun Nam,
Dongjun Chung,
Chrystal M. Paulos,
Bei Liu,
XueZhong Yu,
Caroline C. Philpott,
Philip H. Howe,
Zihai Li
Publication year - 2020
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aaz3865
Subject(s) - immune checkpoint , immune system , tigit , biology , microbiology and biotechnology , effector , immunity , intracellular , t cell , cell , immunology , cancer research , immunotherapy , genetics
Distinct lineages of T cells can act in response to various environmental cues to either drive or restrict immune-mediated pathology. Here, we identify the RNA binding protein, poly(C)-binding protein 1 (PCBP1) as an intracellular immune checkpoint that is up-regulated in activated T cells to prevent conversion of effector T (T) cells into regulatory T (T) cells, by restricting the expression of T cell-intrinsic T commitment programs. This was critical for stabilizing T cell functions and subverting immune-suppressive signals. T cell-specific deletion of favored T cell differentiation, enlisted multiple inhibitory immune checkpoint molecules including PD-1, TIGIT, and VISTA on tumor-infiltrating lymphocytes, and blunted antitumor immunity. Our results demonstrate a critical role for PCBP1 as an intracellular immune checkpoint for maintaining T cell functions in cancer immunity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom